Hysingla ER (Hydrocodone Bitartrate) Patent Expiration, LOE Window & CMS Spending
Hysingla ER (Hydrocodone Bitartrate) by Knoa: FDA Orange Book LOE 2031-12-21, 1 AB generics, $20.7M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Knoa |
| FDA Application & Pathway | N206627 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-12-21 |
| Orange Book Patents (*PED Extensions) | 19 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $20.7M |
| 2024 Medicare Part D Spend | $18.5M |
| 2024 Medicaid Spend | $2.2M |
| Reported Wholesale Price Change (CA SB 17) | 14 WAC filings (max 441.7% 2-yr change) |